These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
658 related articles for article (PubMed ID: 24382646)
1. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis. Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646 [TBL] [Abstract][Full Text] [Related]
2. Metabonomic profiles discriminate hepatocellular carcinoma from liver cirrhosis by ultraperformance liquid chromatography-mass spectrometry. Wang B; Chen D; Chen Y; Hu Z; Cao M; Xie Q; Chen Y; Xu J; Zheng S; Li L J Proteome Res; 2012 Feb; 11(2):1217-27. PubMed ID: 22200553 [TBL] [Abstract][Full Text] [Related]
3. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort. Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175 [TBL] [Abstract][Full Text] [Related]
4. Surface enhanced laser desorption/ionization profiling: New diagnostic method of HBV-related hepatocellular carcinoma. Wu C; Wang Z; Liu L; Zhao P; Wang W; Yao D; Shi B; Lu J; Liao P; Yang Y; Zhu L J Gastroenterol Hepatol; 2009 Jan; 24(1):55-62. PubMed ID: 18823443 [TBL] [Abstract][Full Text] [Related]
5. Serum lipidomic profiling as a useful tool for screening potential biomarkers of hepatitis B-related hepatocellular carcinoma by ultraperformance liquid chromatography-mass spectrometry. Passos-Castilho AM; Carvalho VM; Cardozo KH; Kikuchi L; Chagas AL; Gomes-GouvĂȘa MS; Malta F; de Seixas-Santos Nastri AC; Pinho JR; Carrilho FJ; Granato CF BMC Cancer; 2015 Dec; 15():985. PubMed ID: 26680993 [TBL] [Abstract][Full Text] [Related]
6. Acetylcarnitine Is a Candidate Diagnostic and Prognostic Biomarker of Hepatocellular Carcinoma. Lu Y; Li N; Gao L; Xu YJ; Huang C; Yu K; Ling Q; Cheng Q; Chen S; Zhu M; Fang J; Chen M; Ong CN Cancer Res; 2016 May; 76(10):2912-20. PubMed ID: 26976432 [TBL] [Abstract][Full Text] [Related]
7. Plasma lipidomic fingerprinting to distinguish among hepatitis C-related hepatocellular carcinoma, liver cirrhosis, and chronic hepatitis C using MALDI-TOF mass spectrometry: a pilot study. Passos-Castilho AM; Lo Turco E; Ferraz ML; Matos C; Silva I; Parise E; Pilau E; Gozzo F; Granato C J Gastrointestin Liver Dis; 2015 Mar; 24(1):43-9. PubMed ID: 25822433 [TBL] [Abstract][Full Text] [Related]
8. Identification of 1-Methylnicotinamide as a specific biomarker for the progression of cirrhosis to hepatocellular carcinoma. Zhang S; Tuo P; Ji Y; Huang Z; Xiong Z; Li H; Ruan C J Cancer Res Clin Oncol; 2024 Jun; 150(6):310. PubMed ID: 38890166 [TBL] [Abstract][Full Text] [Related]
9. Serum Metabolomics to Identify the Liver Disease-Specific Biomarkers for the Progression of Hepatitis to Hepatocellular Carcinoma. Gao R; Cheng J; Fan C; Shi X; Cao Y; Sun B; Ding H; Hu C; Dong F; Yan X Sci Rep; 2015 Dec; 5():18175. PubMed ID: 26658617 [TBL] [Abstract][Full Text] [Related]
10. Serum and urine metabolite profiling reveals potential biomarkers of human hepatocellular carcinoma. Chen T; Xie G; Wang X; Fan J; Qiu Y; Zheng X; Qi X; Cao Y; Su M; Wang X; Xu LX; Yen Y; Liu P; Jia W Mol Cell Proteomics; 2011 Jul; 10(7):M110.004945. PubMed ID: 21518826 [TBL] [Abstract][Full Text] [Related]
11. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS. Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807 [TBL] [Abstract][Full Text] [Related]
12. Tissue and serum metabolomic phenotyping for diagnosis and prognosis of hepatocellular carcinoma. Han J; Han ML; Xing H; Li ZL; Yuan DY; Wu H; Zhang H; Wang MD; Li C; Liang L; Song YY; Xu AJ; Wu MC; Shen F; Xie Y; Yang T Int J Cancer; 2020 Mar; 146(6):1741-1753. PubMed ID: 31361910 [TBL] [Abstract][Full Text] [Related]
13. Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. Tangkijvanich P; Chanmee T; Komtong S; Mahachai V; Wisedopas N; Pothacharoen P; Kongtawelert P J Gastroenterol Hepatol; 2010 Jan; 25(1):129-37. PubMed ID: 19793164 [TBL] [Abstract][Full Text] [Related]
14. Metabolomic Characterization of Hepatocellular Carcinoma in Patients with Liver Cirrhosis for Biomarker Discovery. Di Poto C; Ferrarini A; Zhao Y; Varghese RS; Tu C; Zuo Y; Wang M; Nezami Ranjbar MR; Luo Y; Zhang C; Desai CS; Shetty K; Tadesse MG; Ressom HW Cancer Epidemiol Biomarkers Prev; 2017 May; 26(5):675-683. PubMed ID: 27913395 [No Abstract] [Full Text] [Related]
15. Metabolomics study of stepwise hepatocarcinogenesis from the model rats to patients: potential biomarkers effective for small hepatocellular carcinoma diagnosis. Tan Y; Yin P; Tang L; Xing W; Huang Q; Cao D; Zhao X; Wang W; Lu X; Xu Z; Wang H; Xu G Mol Cell Proteomics; 2012 Feb; 11(2):M111.010694. PubMed ID: 22084000 [TBL] [Abstract][Full Text] [Related]
16. Phenotypic Characterization Analysis of Human Hepatocarcinoma by Urine Metabolomics Approach. Liang Q; Liu H; Wang C; Li B Sci Rep; 2016 Jan; 6():19763. PubMed ID: 26805550 [TBL] [Abstract][Full Text] [Related]
17. Serum paraoxonase 1 heteroplasmon, a fucosylated, and sialylated glycoprotein in distinguishing early hepatocellular carcinoma from liver cirrhosis patients. Sun C; Chen P; Chen Q; Sun L; Kang X; Qin X; Liu Y Acta Biochim Biophys Sin (Shanghai); 2012 Sep; 44(9):765-73. PubMed ID: 22751611 [TBL] [Abstract][Full Text] [Related]
18. Metabolomics study of hepatocellular carcinoma: discovery and validation of serum potential biomarkers by using capillary electrophoresis-mass spectrometry. Zeng J; Yin P; Tan Y; Dong L; Hu C; Huang Q; Lu X; Wang H; Xu G J Proteome Res; 2014 Jul; 13(7):3420-31. PubMed ID: 24853826 [TBL] [Abstract][Full Text] [Related]
19. Development of urinary pseudotargeted LC-MS-based metabolomics method and its application in hepatocellular carcinoma biomarker discovery. Shao Y; Zhu B; Zheng R; Zhao X; Yin P; Lu X; Jiao B; Xu G; Yao Z J Proteome Res; 2015 Feb; 14(2):906-16. PubMed ID: 25483141 [TBL] [Abstract][Full Text] [Related]
20. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy. Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]